TNX-2900
Prader-Willi Syndrome (PWS)
Phase 2 ReadyIND Cleared
Key Facts
Indication
Prader-Willi Syndrome (PWS)
Phase
Phase 2 Ready
Status
IND Cleared
Company
About Tonix Pharmaceuticals
Tonix Pharmaceuticals is a clinical-stage biotech focused on addressing difficult-to-treat conditions across CNS, immunology, infectious diseases, and rare diseases. Its strategy leverages multiple technology platforms, including a sublingual delivery system, a live virus vaccine platform, and monoclonal antibody development, to advance a broad pipeline. Key near-term catalysts include Phase 2 data for TNX-102 SL in Acute Stress Disorder and the progression of its Phase 2-ready programs in organ transplant rejection and Prader-Willi Syndrome.
View full company profileTherapeutic Areas
Other Prader-Willi Syndrome (PWS) Drugs
| Drug | Company | Phase |
|---|---|---|
| IMCIVREE® (setmelanotide) | Rhythm Pharmaceuticals | Phase 2 |
| MC4R Agonist(s) for Rare Obesity | Palatin Technologies | Phase 2 / Planning |